Vyant Bio (VYNT)

Vyant Bio (VYNT) Stock Price & Analysis


VYNT Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$0.21 - $4.94
Previous Close$0.22
Average Volume (3M)181.82K
Market Cap
Enterprise Value-$6.41M
Total Cash (Recent Filing)$10.00M
Total Debt (Recent Filing)$2.20M
Price to Earnings (P/E)>-0.1
Aug 14, 2023
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.87
Shares Outstanding6,267,708
10 Day Avg. Volume742,335
30 Day Avg. Volume181,822
Standard Deviation0.36
Financial Highlights & Ratios
Price to Book (P/B)14.42
Price to Sales (P/S)-28.42
Price to Cash Flow (P/CF)-0.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-11.30
Enterprise Value/Gross Profit18.73
Enterprise Value/Ebitda0.42
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0



Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.



What was Vyant Bio’s price range in the past 12 months?
Vyant Bio lowest stock price was $0.21 and its highest was $4.94 in the past 12 months.
    What is Vyant Bio’s market cap?
    Currently, no data Available
    When is Vyant Bio’s upcoming earnings report date?
    Vyant Bio’s upcoming earnings report date is Aug 14, 2023 which is in 77 days.
      How were Vyant Bio’s earnings last quarter?
      Currently, no data Available
      Is Vyant Bio overvalued?
      According to Wall Street analysts Vyant Bio’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
        Does Vyant Bio pay dividends?
        Vyant Bio does not currently pay dividends.
        What is Vyant Bio’s EPS estimate?
        Vyant Bio’s EPS estimate for its next earnings report is not yet available.
        How many shares outstanding does Vyant Bio have?
        Vyant Bio has 6,267,708 shares outstanding.
          What happened to Vyant Bio’s price movement after its last earnings report?
          Currently, no data Available
          Which hedge fund is a major shareholder of Vyant Bio?
          Currently, no hedge funds are holding shares in VYNT


          Vyant Bio Stock Smart Score

          This stock does not have enough of the key information we need to rate it accurately. Smart Score is calculated for stocks traded in Nasdaq, NYSE, TSE and LSE with a market cap above $30M and average 3 months trading volume above $30K.
          Learn more about TipRanks Smart Score

          Company Description

          Vyant Bio

          Cancer Genetics, Inc. engages in the development, commercialization, and sale of molecular and biomarker-based tests and services. Through its Select One Clinical Trials program, the firm provides a range of clinical trial services for both oncology and non-oncology genetic testing such as bioinformatics, biomarker solutions, bio repository solutions, consulting, cytogenetic testing, nucleic acid extraction and purification, flow cytometry, Focus::NGS Panel, gene expression analyses, genotyping, and pharmacogenomics. The company was founded by Raju S. K. Chaganti on April 8, 1999 and is headquartered in Rutherford, NJ.


          Top 5 ETFs holding VYNT

          Currently, no data available
          Please return soon. This page is being updated.
          Up to five ETFs with an Outperform Smart Score that hold VYNT. The ETFs are listed according to market value of VYNT within the ETF


          Forecast EPS vs Actual EPS

          Currently, no data available
          Please return soon. This page is being updated.

          Similar Stocks
          Price & Change
          Soleno Therapeutics
          Ensysce Biosciences
          Statera BioPharma

          Popular Stocks

          What's Included in PREMIUM?
          Make informed decisions based on Top Analysts' activity
          Know what industry insiders are buying
          Get actionable alerts from top Wall Street Analysts
          Find out before anyone else which stock is going to shoot up
          Get powerful stock screeners & detailed portfolio analysis